Medicinal Chemistry News and Research

RSS

AACP to honor UW professor with Volwiler Research Achievement Award

The American Association of Colleges of Pharmacy will honor Sidney D. Nelson, Ph.D., from the University of Washington for his outstanding research and contributions to the field of pharmaceutical sciences.

22 Mar 2011

Pharmaron signs agreement to provide Isis with nucleoside phosphoramidites up to 100 kg

Pharmaron has signed an agreement to provide Isis Pharmaceuticals, Inc. with nucleoside phosphoramidites at quantities up to 100 kg. Nucleoside phosphoramidites are fundamental building blocks in the production of antisense therapeutics.

17 Mar 2011

InhibOx and COSMIC discoveries align to deliver full service drug discovery offering

InhibOx Ltd (spin-out of Oxford, UK) and the COSMIC Discoveries (the independent service arm of the Institute of Life Sciences, Hyderabad, India) today announce that they have formed a close strategic partnership to deliver a full service drug discovery service offering, incorporating expert computational, medicinal and synthetic chemistry design capabilities. Both commercial organizations, linked to world-leading academic institutes, have built their services on advanced proprietary science and technology. Together, they offer unique capabilities that are able to address the most demanding drug discovery challenges on behalf of biotech and pharmaceutical companies worldwide.

15 Mar 2011

ITCs in vegetables appear to target and block p53 gene linked with cancer

Scientists are reporting discovery of a potential biochemical basis for the apparent cancer-fighting ability of broccoli and its veggie cousins. They found for the first time that certain substances in the vegetables appear to target and block a defective gene associated with cancer.

10 Mar 2011

Discovery of potent class of anti-cancer compounds by Scripps Research and MIT scientists

Working as part of a public program to screen compounds to find potential medicines and other biologically useful molecules, scientists from The Scripps Research Institute and Massachusetts Institute of Technology (MIT) have discovered an extremely potent class of potential anti-cancer and anti-neurodegenerative disorder compounds.

8 Mar 2011

IAVI, THSTI collaborate to establish HIV Vaccine Design Program in India

The Translational Health Sciences and Technology Institute, an autonomous institute of the Indian government's Department of Biotechnology, and the International AIDS Vaccine Initiative announced today an agreement to jointly establish, operate and fund an HIV Vaccine Design Program in India.

2 Mar 2011

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 1819698 to Rexahn for its novel anti-cancer quinoxalinyl-piperazine compounds.

28 Feb 2011

Selcia completes drug discovery project with ExonHit Therapeutics using fragment screening technology

Selcia Ltd today announced the successful completion of a drug discovery project with ExonHit Therapeutics SA, using Selcia's fragment screening technology. Novel and weak affinity hits were identified from Selcia's Fragment Library, using their proprietary CEfrag technique.

28 Feb 2011

Less-toxic combination of immune-based drug and chemotherapy drug produce long-term remissions in CLL

New research shows that a less-toxic combination of a targeted immune-based drug and a chemotherapy drug can produce long-term remissions in some chronic lymphocytic leukemia patients. And it does so without increasing the risk of later therapy-related myelodysplastic syndrome and acute myeloid leukemia, which can often occur with a three-drug combination used to treat these patients.

25 Feb 2011

Aminothiazoles as therapeutic leads for prion diseases

Scientists who examined more than 10,000 chemical compounds during the last year in search of potential new drugs for a group of untreatable brain diseases, are reporting that one substance shows unusual promise.

24 Feb 2011

BioTime to merge Glycosan with OrthoCyte

BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has signed a definitive agreement to merge Utah-based Glycosan BioSystems, Inc. (Glycosan) with BioTime's wholly-owned subsidiary, OrthoCyte Corporation. The acquisition is expected to close by March 18, 2011.

14 Feb 2011

Novel technique could speed up the development of peptide-based drugs against cancer

Researchers at the University at Buffalo have devised two new ways of "stapling" peptide helices to prevent these medically important molecules from losing their shape and degrading in the presence of enzymes.

9 Feb 2011

AMRI fourth quarter total revenue increases 12% to $48.6 million

AMRI today reported financial and operating results for the fourth quarter and full year ended December 31, 2010.

7 Feb 2011

Largazole appears to be an ideal blueprint for developing new drugs against bone diseases

One of Mother Nature's latest gifts to medical science is stirring excitement with the discovery that the substance - obtained from a coral-reef inhabiting cyanobacterium - appears to be an ideal blueprint for developing new drugs for serious fractures, osteoporosis, and other bone diseases.

3 Feb 2011

ALS Biopharma receives ADDF grant to develop therapeutics against Alzheimer's disease

The Alzheimer's Drug Discovery Foundation announced today that it has awarded a grant of $195,000 to ALS Biopharma, LLC to develop therapeutics targeted at clearing toxic proteins implicated in Alzheimer's disease.

28 Jan 2011

McGill, GSK enter collaborative research agreement on cystic fibrosis

McGill University and GlaxoSmithKline plc have signed a collaboration agreement to develop a potential breakthrough approach to treat cystic fibrosis, a fatal genetic disease. The trans-Atlantic effort between researchers from McGill's Faculty of Medicine and their GSK collaborators in the UK, will focus on developing molecules that could treat the disease by correcting the dysfunction caused by the mutated gene.

28 Jan 2011

Small molecules may inhibit entry of Ebola into human cells

Ebola, a virus that causes deadly hemorrhagic fever in humans, has no known cure or vaccine. But a new study by University of Illinois at Chicago scientists has uncovered a family of small molecules which appear to bind to the virus's outer protein coat and may inhibit its entry into human cells.

20 Jan 2011

Harbor Biosciences signs development agreements for HE2000, HE3235 and HE3286 with CIPI

Harbor BioSciences, Inc., a leader in the development of a proprietary class of adrenal steroid hormones as novel pharmaceuticals, announced it has licensed the research and development and commercialization rights for three of its products, exclusively in the People's Republic of China and Hong Kong, to China State Institute of Pharmaceutical Industry (CIPI).

18 Jan 2011

Vanderbilt, Scripps Research form partnership to open new institute

The Scripps Research Institute and Vanderbilt University have formed a partnership to advance science at the interface of chemistry and medicine, the institutions announced today.

14 Jan 2011

VENENUM Biodesign relocates to new, state-of-the-art facility in Hamilton

VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify hits against its novel disease-based targets or its partners' targets, announced today its relocation to a brand-new, state-of-the-art facility in Hamilton, NJ in Mercer County.

5 Jan 2011